Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-18
2011-10-18
Kifle, Bruck (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
08039464
ABSTRACT:
The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, systemic sclerosis, pneumoconiosis or lung cancer. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.
REFERENCES:
patent: 2648667 (1953-08-01), Sternbach
patent: 3177252 (1965-04-01), Thominet et al.
patent: 3406168 (1968-10-01), Schmidt et al.
patent: 3660380 (1972-05-01), Schmidt et al.
patent: 4021557 (1977-05-01), Schmidt et al.
patent: 4210648 (1980-07-01), Schmidt et al.
patent: 4213984 (1980-07-01), Schmidt et al.
patent: 4277399 (1981-07-01), Diethelm
patent: 4308206 (1981-12-01), Gerszberg
patent: 4317823 (1982-03-01), Rainer
patent: 4335250 (1982-06-01), Umezawa et al.
patent: 4381301 (1983-04-01), Rainer
patent: 4424222 (1984-01-01), Engel et al.
patent: 4424226 (1984-01-01), Eberlein et al.
patent: 4724236 (1988-02-01), Eberlein et al.
patent: 4863920 (1989-09-01), Hunkeler et al.
patent: 5140025 (1992-08-01), Grundler et al.
patent: 5324832 (1994-06-01), Jacobson et al.
patent: 5366972 (1994-11-01), Hargrave et al.
patent: 5576436 (1996-11-01), McCabe et al.
patent: 5620978 (1997-04-01), Cai et al.
patent: 5705499 (1998-01-01), Cywin et al.
patent: 5712269 (1998-01-01), McCabe et al.
patent: 5716952 (1998-02-01), WoldeMussie et al.
patent: 5817679 (1998-10-01), Shen et al.
patent: 5935781 (1999-08-01), Poirier
patent: 6022683 (2000-02-01), Poirier
patent: 6060473 (2000-05-01), Shen et al.
patent: 6077846 (2000-06-01), Qian et al.
patent: 6117889 (2000-09-01), Shen et al.
patent: 6255490 (2001-07-01), Shen et al.
patent: 6306861 (2001-10-01), Leonardi et al.
patent: 6316423 (2001-11-01), Von Lubitz et al.
patent: 6365592 (2002-04-01), Leblanc et al.
patent: 6403584 (2002-06-01), de Laszlo et al.
patent: 6403594 (2002-06-01), Leonardi et al.
patent: 6410583 (2002-06-01), Labelle et al.
patent: 6486163 (2002-11-01), Leonardi et al.
patent: 6528529 (2003-03-01), Brann et al.
patent: 6537524 (2003-03-01), Hassan et al.
patent: 6579889 (2003-06-01), de Laszlo et al.
patent: 6588354 (2003-07-01), Gai
patent: 6608055 (2003-08-01), Sieger et al.
patent: 6620323 (2003-09-01), Hother et al.
patent: 6627644 (2003-09-01), Brotherton-Pleiss et al.
patent: 6635658 (2003-10-01), Madera et al.
patent: 6680319 (2004-01-01), Leonardi et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 6699866 (2004-03-01), Cuny et al.
patent: 6716857 (2004-04-01), Kim et al.
patent: 6756392 (2004-06-01), Magee
patent: 6759419 (2004-07-01), Kim et al.
patent: 0 330 756 (1989-09-01), None
patent: 0429987 (1991-06-01), None
patent: 0 834 512 (1998-04-01), None
patent: 1505795 (1967-12-01), None
patent: 2 239 396 (1991-07-01), None
patent: 8100747 (1981-03-01), None
patent: WO 2004/052847 (2004-06-01), None
Barnes, “New Drugs for Asthma”, Nature Reviews, vol. 3, Oct. 2004, pp. 831-844.
Beneke et al., “Poly(ADP-Ribosyl)ation Inhibitors: Promising Drug Candidates for a Wide Variety of Pathophysiologic Conditions”, Int. J. Cancer, vol. 111, 2004, pp. 813-818.
Carlsen, “Therapeutic strategies for allergic airways disease”, Paediatric Respiratory Review, (2004), 5, pp. 45-51.
Faro et al., “Myocardial Protection by PJ34, a Novel Potent Poly (ADP-Ribose) Synthetase Inhibitor”, 2002 by the Society of Thoracic Surgeons, pp. 575-581.
Hageman et al., Systemic Poly(ADP-Ribose) Polymerase-1 Activation, Chronic Inflammation, and Oxidative Stress in COPD Patients, Free Radical Biology & Medicine, vol. 35, No. 2, pp. 140-148, 2003.
Maione et al., “Apoptotic Genes Expression in the Lumbar Dorsal Horn in a Model Neuropathic Pain in Rat”, Somatosensory Systems, Pain, vol. 13, No. 21, Jan. 2002, pp. 101-106.
Martin-Oliva et al., “Crosstalk between PARP-1 and NF-kB Modulates the Promotion of Skin Neoplasia”, Oncogene, (2004), 23, pp. 5275-5283.
Mobley, “Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance?”, Medical Hypotheses, (2004) 62, pp. 839-843.
Murakami et al, “Inhibition of Poly(ADP-Ribose) Polymerase Attenuates Acute Lung Injury in an Ovine Model of Sepsis”, Shock, vol. 21, No. 2, pp. 126-133, 2004.
Virag et al., “Effects of poly(ADP-Ribose) Polymerase Inhibition on Inflammatory Cell Migration in a Murine Model of Asthma”, Med Sci Monit, 2004, 10(3), BR77-83.
Boulares et al., “Gene Knockout or Pharmacological inhibition of Poly(ADP-Ribose) Polymerase-1 Prevents Lung Inflammation in a murine Model of Asthma”, Am. J. Respir. Cell Mol. Biolo. vol. 28, pp. 322-329, 2003.
Clark et al., “Pathogenesis of Malaria and Clinically Similar Conditions”, Clinical Microbiology Reviews, Jun. 2004, vol. 17, No. 3, pp. 504-539.
Furst et al, “Updated consensus statement on biological agents for the treatment of rheumatoid arthritis andother immune mediated inflammatory diseases (May 2003)”, Ann Rheum Dis, 2003, 62 (Suppl II), pp. ii2-ii9.
Pascual et al., “A Poly(ADP-Ribose) Polymerase Haplotype Spanning the Promoter Region Confers Susceptibility to rheumatoid Arthritis”, Arthritis & Rheumatism, vol. 48, No. 3, Mar. 2003, pp. 638-641.
Database Biosis ′Online!, Pompilio et al., “Comparative Evaluations on Short-Term Treatment with Cimetidine and Pirenzepine in Duodenal Ulcer and in Acute Inflammatory Pathology of the Stomach and Duodenum”, Database accession No. PREV198375090208 abstract & Rassegna Di Medicina Sperimentale, vol. 28, No. 9, 1981, pp. 567-574.
Database Embase ′Online!, Londong W., “Present status and future perspectives of muscarinic receptor antagonists”, Database accession No. EMB-1987043228 abstract & Scandinavian Journal of Gastroenterology, Supplement, 1986 Norway, vol. 21, No. Suppl. 125, 1986, pp. 55-60.
Cazzola et al., “An M-1-Selective Muscarinic Receptor Antagonist Telenzepine Improves Lung Function in Patients with Chronic Obstructive Bronchitis”, Pulmonary Pharmacology, vol. 3, No. 4, 1990, pp. 185-189.
Database Biosis ′Online!, Bustos-Fernandez et al., “Pirenzepine as Anti-Inflammatory Drug in a Model of Experimental Colitis in Rat”, Database accession No. PREV198885114571, abstract, & ACTA Physiologica et Pharmacologica Latinoamericana, vol. 37, No. 4, 1987, pp. 415-422.
Database Biosis ′Online!, Matsui Shinobu et al., “Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor”, Database accession No. PREV200200011312 abstract & Journal of Cardiovascular Pharmacology, vol. 38, No. Supplement 1, Oct. 2001, pp. S43-S49.
Cu Jun, “Effects of Hydrochloric Pirenzepine Treating Reflu Esophagitis”, Journal fo Medicine Tribune, vol. 24, No. 22, 2003, pp. 18-19, (Abstract only).
Office Action dated Mar. 6, 2009 in CN 2005 80 027 832.1 and an English translation.
Xu Zhengfu, “Application of Pirenzepine in Digestion Disease”, Medicine of Communication, vol. 9, No. 1, 1995, pp. 28-30. (Translation).
Kifle Bruck
ProteoSys AG
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Muscarinic antagonists with PARP and SIR modulating activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Muscarinic antagonists with PARP and SIR modulating activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muscarinic antagonists with PARP and SIR modulating activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298443